Abstract
Atrial fibrillation is the most common clinically significant cardiac arrhythmia and is associated with markedly increased risks of cardiovascular diseases. Atrial fibrillation and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a blocker of the reninangiotensin system, may postpone or prevent development of atrial fibrillation and reduce thromboembolic complications. Awareness of the risk of developing atrial fibrillation in hypertensives may be of great importance and focus on prevention of atrial fibrillation development with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, atrial fibrillation, hypertension, renin-angiotensin system, cardiac arrhythmia, cardiovascular diseases, thromboembolic complications, Framingham Heart Study, systolic blood pressure, electrocardiogram, ANTIHYPERTEN-SIVE TREATMENT, RAS-blockade, cardiac hypertrophy, left ventricular hypertrophy, beta-blocker, valsartan, calcium channel blockers, (lisinopril), (doxazosin), (chlorthalidone), (losartan), (amlodipine), atenolol/amlodipine, telmisartan, ESH/ESC guidelines, anti-arrhythmic drugs, (ramipril), (irbesartan), myocardial infarction, diltiazem, Diuretics, hydrochlorothiazide, Alpha-Adrenoreceptor Blocker
Current Vascular Pharmacology
Title: A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention
Volume: 8 Issue: 6
Author(s): Tonje A. Aksnes and Sverre E. Kjeldsen
Affiliation:
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, atrial fibrillation, hypertension, renin-angiotensin system, cardiac arrhythmia, cardiovascular diseases, thromboembolic complications, Framingham Heart Study, systolic blood pressure, electrocardiogram, ANTIHYPERTEN-SIVE TREATMENT, RAS-blockade, cardiac hypertrophy, left ventricular hypertrophy, beta-blocker, valsartan, calcium channel blockers, (lisinopril), (doxazosin), (chlorthalidone), (losartan), (amlodipine), atenolol/amlodipine, telmisartan, ESH/ESC guidelines, anti-arrhythmic drugs, (ramipril), (irbesartan), myocardial infarction, diltiazem, Diuretics, hydrochlorothiazide, Alpha-Adrenoreceptor Blocker
Abstract: Atrial fibrillation is the most common clinically significant cardiac arrhythmia and is associated with markedly increased risks of cardiovascular diseases. Atrial fibrillation and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a blocker of the reninangiotensin system, may postpone or prevent development of atrial fibrillation and reduce thromboembolic complications. Awareness of the risk of developing atrial fibrillation in hypertensives may be of great importance and focus on prevention of atrial fibrillation development with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.
Export Options
About this article
Cite this article as:
A. Aksnes Tonje and E. Kjeldsen Sverre, A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563807
DOI https://dx.doi.org/10.2174/157016110793563807 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Platelet Function and Signaling by Flavonoids
Mini-Reviews in Medicinal Chemistry Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme
Current Medicinal Chemistry Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Alzheimer’s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets The Effect of Antihypertensive Drugs on Carotid Intima Media Thickness: An Up-to-Date Review
Current Medicinal Chemistry Metabolomic and Imaging: A Literature Review
Current Medical Imaging The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Dark Chocolate and Blood Pressure: A Novel Study from Jordan
Current Drug Delivery Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Obstetrical Hemorrhage Review
Current Women`s Health Reviews Vitamin D in Chronic Kidney Disease: New Potential for Intervention
Current Drug Targets High Glucose-Mediated Imbalance of Nitric Oxide Synthase and Dimethylarginine Dimethylaminohydrolase Expression in Endothelial Cells
Current Neurovascular Research Modulation of Renin-Angiotensin System and Arterial Stiffness: Evidence from Clinical Trials
Current Hypertension Reviews Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Targeted Therapy of Breast Cancer
Current Pharmaceutical Design Lessons from the REACH Registry in Europe
Current Vascular Pharmacology The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
Current Vascular Pharmacology Epidemiological and Clinical Data of Amniotic Fluid Embolism in Forensic Settings
Current Pharmaceutical Biotechnology Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews